NCT05498220 2025-09-02
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
UNC Lineberger Comprehensive Cancer Center
Royal Marsden NHS Foundation Trust
The University of Hong Kong
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
National Cancer Institute (NCI)